Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
Disability
Late-onset NMOSD
Latin america
Neuromyelitis optica spectrum disorder
Prognosis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
24
11
2019
accepted:
05
01
2020
revised:
02
01
2020
pubmed:
15
1
2020
medline:
9
2
2021
entrez:
15
1
2020
Statut:
ppublish
Résumé
We aimed to assess the clinical, paraclinical, imaging and prognostic features of patients with late-onset neuromyelitis optica spectrum disorder (LO-NMOSD; ≥ 50 years at disease onset) LO-NMOSD, compared with early onset-NMOSD (EO-NMOSD, ≤ 49 years at disease onset), in Latin American (LATAM). We retrospectively reviewed the medical records of patients with NMOSD, as defined using the 2015 validated diagnostic criteria. We included patients from Argentina, Brazil and Venezuela. They were divided into: LO-NMOSD and EO-NMOSD and comparison among the groups were performed. Among these 140 NMOSD patients, 24 (17.1%) were LO-NMOSD; 64% were positive for aquaporin-4 antibodies; and 41.5% of this population cohort was non-Caucasian. Severe disability [expanded disability status scale (EDSS) ≥ 6] at the last follow-up and presence of comorbidities were significantly associated with LO-NMOSD, compared with EO-NMOSD. LO-NMOSD patients had a shorter median time to EDSS ≥ 4 than EO-NMOSD patients (46 vs. 60 months; log-rank test p = 0.0006). Furthermore, we observed a positive correlation between age at onset and EDSS score at the last follow-up (Spearman r = 0.34, p < 0.0001). LO-NMOSD patients from LATAM developed early severe disability, compared with EO-NMOSD. Therefore, age at onset could have important implications for the long-term prognosis of NMOSD patients.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to assess the clinical, paraclinical, imaging and prognostic features of patients with late-onset neuromyelitis optica spectrum disorder (LO-NMOSD; ≥ 50 years at disease onset) LO-NMOSD, compared with early onset-NMOSD (EO-NMOSD, ≤ 49 years at disease onset), in Latin American (LATAM).
METHODS
METHODS
We retrospectively reviewed the medical records of patients with NMOSD, as defined using the 2015 validated diagnostic criteria. We included patients from Argentina, Brazil and Venezuela. They were divided into: LO-NMOSD and EO-NMOSD and comparison among the groups were performed.
RESULTS
RESULTS
Among these 140 NMOSD patients, 24 (17.1%) were LO-NMOSD; 64% were positive for aquaporin-4 antibodies; and 41.5% of this population cohort was non-Caucasian. Severe disability [expanded disability status scale (EDSS) ≥ 6] at the last follow-up and presence of comorbidities were significantly associated with LO-NMOSD, compared with EO-NMOSD. LO-NMOSD patients had a shorter median time to EDSS ≥ 4 than EO-NMOSD patients (46 vs. 60 months; log-rank test p = 0.0006). Furthermore, we observed a positive correlation between age at onset and EDSS score at the last follow-up (Spearman r = 0.34, p < 0.0001).
CONCLUSION
CONCLUSIONS
LO-NMOSD patients from LATAM developed early severe disability, compared with EO-NMOSD. Therefore, age at onset could have important implications for the long-term prognosis of NMOSD patients.
Identifiants
pubmed: 31932911
doi: 10.1007/s00415-020-09699-2
pii: 10.1007/s00415-020-09699-2
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260-1268Références
Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815
doi: 10.1016/S1474-4422(07)70216-8
Carnero Contentti E, De Virgiliis M, Hryb JP et al (2019) Aquaporin-4 serostatus and visual outcomes in clinically isolated acute optic neuritis. J Neuroophthalmol 39(2):165–169
doi: 10.1097/WNO.0000000000000668
Akman-Demir G, Tüzün E, Waters P et al (2011) Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 258(3):464–470
doi: 10.1007/s00415-010-5780-4
Wingerchuk D, Banwell B, Bennett J et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189
doi: 10.1212/WNL.0000000000001729
Lennon V, Wingerchuk D, Kryzer T et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112
doi: 10.1016/S0140-6736(04)17551-X
Sepulveda M, Armangue T, Sola-Valls N et al (2016) Neuromyelitis optica spectrum disorders. Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 3:e225
doi: 10.1212/NXI.0000000000000225
Waters P, McKeon A, Leite MI et al (2012) Serological diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78:665–671
doi: 10.1212/WNL.0b013e318248dec1
Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273–1277
doi: 10.1212/WNL.0b013e31826aac4e
Hamid SHM, Whittam D, Mutch K et al (2017) What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol 264:2088–2094
doi: 10.1007/s00415-017-8596-7
Palace J, Lin DY, Zeng D et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142:1310–1323
doi: 10.1093/brain/awz054
Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834–1849
doi: 10.1093/brain/aws109
Collongues N, Marignier R, Zephir H et al (2010) Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 74:736–742
doi: 10.1212/WNL.0b013e3181d31e35
Nagaishi A, Takagi M, Umemura A et al (2011) Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 82:1360–1364
doi: 10.1136/jnnp-2011-300403
Collongues N, Marignier R, Jacob A et al (2014) Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler 20:1086–1094
doi: 10.1177/1352458513515085
Fragoso YD, Ruocco HH, Dias RM et al (2019) Late onset of neuromyelitis optica spectrum disorders. Neurol Ther. https://doi.org/10.1007/s40120-019-0143-2 (Epub ahead of print)
doi: 10.1007/s40120-019-0143-2
pubmed: 31267407
pmcid: 6858916
Zhang LJ, Yang LN, Li T et al (2017) Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders. Int J Neurosci 127(4):334–338
doi: 10.1080/00207454.2016.1254630
Mao Z, Yin J, Zhong X et al (2015) Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population. BMC Neurol 15:160
doi: 10.1186/s12883-015-0417-y
Seok JM, Cho HJ, Ahn SW et al (2017) Clinical characteristics of late-onset neuromyelitis optica spectrum. Mult Scler 23(13):1748–1756
doi: 10.1177/1352458516685416
Sepulveda M, Delgado-García G, Blanco Y et al (2019) Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. Neurol Neuroimmunol Neuroinflamm 6(6):e607
doi: 10.1212/NXI.0000000000000607
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
doi: 10.1212/WNL.33.11.1444
Bedoya G, Montoya P, García J et al (2006) Admixture dynamics in Hispanics: a shift in the nuclear genetic ancestry of a South American population isolate. Proc Natl Acad Sci USA 103:7234–7239
doi: 10.1073/pnas.0508716103
Carnero Contentti E, Daccach Marques V, Soto de Castillo I et al (2018) Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: a cohort of Latin American patients. Mult Scler Relat Disord 19:73–78
doi: 10.1016/j.msard.2017.11.004
Carnero Contentti E, Soto de Castillo I, Daccach Marques V et al (2018) Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. Mult Scler Relat Disord 20:109–114
doi: 10.1016/j.msard.2018.01.001
Mealy MA, Mossburg SE, Kim SH et al (2018) Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord 28:64–68
doi: 10.1016/j.msard.2018.12.011
Wingerchuk DM, Pittock SJ, Lucchinetti CF et al (2007) A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68:603–605
doi: 10.1212/01.wnl.0000254502.87233.9a
Krumbholz M, Hofstadt-van Oy U, Angstwurm K et al (2015) Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol 262:1379–1384
doi: 10.1007/s00415-015-7766-8
Marrie RA (2019) Comorbidity in multiple sclerosis: past, present and future. Clin Investig Med 42(1):E5–E12
doi: 10.25011/cim.v42i1.32383